title: China: current trends in pharmaceutical drug discovery.
abstract: Pharmaceutical discovery and development is expensive and highly risky, even for multinational corporations. As a developing country with limited financial resources, China has been seeking the most cost-effective means to reach the same level of innovation and productivity as Western countries in the pharmaceutical industry sector. After more than 50 years of building up talent and experience, the time for China to become a powerhouse in pharmaceutical innovation is finally approaching. Returnee scientists to China are one of the reasons for the wave of new discovery and commercialization occurring within the country. The consolidation of local Chinese pharmaceutical companies and foreign investment is also providing an agreeable environment for the evolution of a new generation of biotechnology. The opportunity for pharmaceutical innovation is also being expedited by the entry of multinational companies into the Chinese pharmaceutical market, and by the outsourcing of research from these companies to China.
authors: Shanghai Genomics Inc and GNI Ltd, 647 Song Tao Road, Building 1, Shanghai Zhangjiang Hi-Tech Park, Shanghai 201203, China. yluo@shanghaigenomics.com
authors: Ying
authors: Y
authors: Luo
mesh_terms: D001709:Biotechnology / Q000191:economics / Q000639:trends; D002681:China; D015195:Drug Design; D004345:Drug Industry / Q000191:economics / Q000639:trends; D006801:Humans; D010601:Pharmacology, Clinical / Q000191:economics / Q000639:trends*; D012106:Research